[Seungkwon Kim, Edaily Reporter] South Korea’s pharmaceutical and biotech sector experienced significant volatility on August 13, driven by growth themes in obesity/medical aesthetics, hair loss, and immuno-oncology.

#GCWellbeing surged about 17% on positive Phase 3 data from China for its fat-dissolving injectable RZL-012. #JWPharmaceutical rose roughly 11% on hopes for expanded reimbursement coverage for its hair-loss drug. #Genexine gained about 16% on renewed attention to its DNA vaccine platform and the resolution of an international arbitration dispute. Each rally reflected a distinct growth story rather than near-term earnings gains.

GC Wellbeing: China Phase 3 Success Validates One-to-Two-Dose Fat Reduction

GC Wellbeing closed up about 17% at 10,750 won after its partner, Raziel Therapeutics, reported that RZL-012 met key efficacy and safety endpoints in a Chinese Phase 3 trial. The pivotal study, which enrolled 480 adults with submental fullness, was conducted jointly by Raziel and JuveStar, an affiliate of Fosun Pharma. RZL-012 met both primary and secondary endpoints at day 84 following a single treatment, with a response rate more than 30 percentage points higher than the placebo. Fosun and Raziel plan to file for approval with China’s NMPA by year-end and are pursuing clinical trials to expand the treatment to the abdomen and thighs.

RZL-012 destroys targeted fat cells and is designed to work with just one or two injections, compared to multiple sessions required for existing products. GC Wellbeing licensed the domestic rights and made a strategic equity investment in Raziel in June.

A company official stated, “This result confirms RZL-012’s commercial potential. We will build a differentiated portfolio linking obesity care and medical aesthetics around this asset.”

The success in China does not guarantee a domestic approval timeline—Korean regulatory strategy and pricing still need to be worked out, making the local launch schedule the true test of long-term value.

JW Pharmaceutical: Hopes for Hair-Loss Reimbursement Fuel Rally

JW Pharmaceutical closed up about 11% at 3,430 won, as hair-loss treatment emerges as the next growth category following obesity drugs and reports circulate that the government is reviewing expanded insurance coverage. However, neither the scope nor the timing has been confirmed, so some of the optimism may be getting ahead of the fundamentals.

The company’s product lineup includes the oral drugs Monad Tab (finasteride) and Dutamoa Tab (dutasteride), the topical minoxidil product Mydil, and the licensed Rogaine Foam, supported by a clinic-focused sales network in dermatology and urology. It has also expanded into hair-care products through Galderma Korea and Pierre Fabre, and is co-developing a topical treatment, AD-303.

Group synergy is another factor: affiliate JW Central recently licensed a twice-monthly GLP-1 obesity drug from China’s Gan & Lee for $85 million and is developing its own hair-loss candidate, JW0061—with JW Central handling hospital sales and global licensing while JW Pharmaceutical co-markets through clinics, a model already used for the cholesterol drug Livalo.

A JW Central official said co-marketing arrangements would expand “once JW Central’s new drugs are commercialized.”

Genexine Rises 16% on Renewed Focus on $200M Arbitration Win

Genexine closed up about 16% at 3,260 won, with no new disclosures but renewed attention on its decisive ICC arbitration victory against U.S.-based Ichor Medical Systems regarding the electroporation device used in its cervical cancer DNA vaccine candidate, GX-188E. Ichor had alleged unauthorized use of its TriGrid device and sought up to $145.6 million in damages; the tribunal dismissed all claims and ordered Ichor to cover approximately 2.2 billion won of Genexine’s legal costs. On August 31, Genexine filed a petition with the U.S. District Court for the Southern District of California to confirm and enforce the award.

Analysts note that resolving this legal uncertainty is distinct from restoring enterprise value, which still depends on progress in clinical trials and commercialization. One industry source said the rally “reflects the resolution of legal uncertainty and demand for a re-rating of the technology assets, but whether it holds depends on actual business results—investors should remain cautious.”